EGFR Antisense DNA

BIOLOGICAL3 trials

Sponsors

University of Pittsburgh, The University of Texas Health Science Center at San Antonio

Conditions

Carcinoma, Squamous Cell of Head and NeckHead and Neck CancerSquamous Cell CarcinomaSquamous Cell Carcinoma of the Head and NeckSquamous Cell Carcinoma, Head And Neck

Phase 1

Gene Therapy in Treating Patients With Advanced Head and Neck Cancer

CompletedNCT00009841

University of PittsburghHead and Neck Cancer

Start: 1999-03-31End: 2002-03-31Updated: 2016-02-12

Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma

TerminatedNCT00903461

University of PittsburghCarcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma, Head And Neck, Squamous Cell Carcinoma of the Head and Neck

Start: 2012-04-30End: 2016-08-31Updated: 2017-02-15

Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma

CompletedNCT01592721

The University of Texas Health Science Center at San AntonioHead and Neck Cancer, Squamous Cell Carcinoma

Start: 2013-04-30End: 2022-02-01Updated: 2022-09-21

Related Papers

Phase I study of cetuximab, intensity-modulated radiotherapy (C-IMRT), and intratumoral EGFR antisense (AS) DNA in patients with locally advanced head and neck cancer (HNC).

Journal of Clinical Oncology2015-05-20